Analyst firms · Jefferies · REGN

Jefferies REGN price target and rating history

Regeneron Pharmaceuticals Inc. (REGN) · Health Care

Jefferies rates Regeneron Pharmaceuticals Inc. (REGN) Buy with a $925 price target, as of its latest action on Mar 24, 2023. It has published 3 rating actions on REGN since June 2022, including 2 upgrades and 0 downgrades. Across 10 firms with a REGN price target in the last 12 months, the median target is $782.50.

Current rating

Buy

Price target

$925

Median target, all firms

$782.50

Actions on REGN

3

Jefferies price target on REGN

Every Jefferies rating on REGN

• Mar 24, 2023
  UpgradeJefferies upgrades to Buy from Hold, price target $675 to $925
• Sep 9, 2022
  UpgradeJefferies upgrades to Hold from Underperform, price target $536 to $675
• Jun 6, 2022
  InitiateJefferies starts coverage at Underperform, price target $536

How other firms rate REGN

Each firm's latest rating and stated target in the last 12 months.

Questions about Jefferies and REGN

What is Jefferies's price target for REGN?

Jefferies's latest stated price target for Regeneron Pharmaceuticals Inc. (REGN) is $925, from its action on Mar 24, 2023.

What is Jefferies's rating on REGN?

Jefferies rates REGN Buy, a bullish rating, as of Mar 24, 2023.

When did Jefferies last change its view on REGN?

On Mar 24, 2023, Jefferies upgrades to Buy from Hold, price target $675 to $925.

How does Jefferies's REGN target compare with other analysts?

Across 10 firms with a REGN price target in the last 12 months, the median target is $782.50.

More REGN rating histories

• Citigroup3
• Leerink Partners9
• BofA Securities3
• Morgan Stanley7
• Truist Securities3
• Bernstein3
• Raymond James3
• Oppenheimer3
• The Benchmark Company3
• H.C. Wainwright5

All Jefferies ratingsREGN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.